WASHINGTON — When President Trump announced the administration’s deal to cut prices for weight-loss drugs, he proclaimed that “you will pay the lowest price anywhere in the world.” But state Medicaid programs might already be getting lower prices, according to a research firm.
Most-favored nation pricing is the main feature of the five deals that the administration has struck with Pfizer, AstraZeneca, EMD Serono, Novo Nordisk, and Eli Lilly. Companies have agreed to sell drugs to Medicaid at prices that are similar to what they charge other countries. Trump has consistently described the most-favored nation prices as the lowest price among comparable countries.
It’s not.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
